Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine the progression-free survival rate in patients with
extensive-stage small cell lung cancer who had achieved complete response, partial response,
or stable disease with their previous platinum chemotherapy regimen, such as cisplatin or
carboplatin in combination with etoposide or irinotecan. In addition, the safety and
effectiveness of sunitinib will also be evaluated.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center